nervous system involvement and in patients that had received B-cell-depleting therapy [17] [18] [19] . Furthermore, intrarenal BAFF production accompanied by local B-cell infiltration was described in lupus nephritis [20, 21] . However, the correlation of serum BAFF levels with SLE disease activity is controversial [17, [22] [23] [24] . Interestingly, mRNA levels of BAFF seem to correlate better with disease activity than serum BAFF protein levels [25] . Therapeutically, in mouse models of SLE, BAFF neutralization was found to reduce disease activity, including renal involvement and mortality [26] . Recently belimumab, a monoclonal antibody targeting soluble human BAFF, has been approved as an add-on to standard therapy to treat adult autoantibody-positive SLE patients with active disease [27] [28] [29] .
Independent of artificially generated monoclonal antibodies such as belimumab, autoantibodies with reactivity to human BAFF have been detected in SLE. The occurrence of such autoantibodies is not surprising considering the fact that patients suffering from SLE may produce a wide variety of autoantibodies targeting cytokines [30] [31] [32] . Anti-BAFF autoantibody levels were increased in adult patients from two different cohorts as well as in paediatric patients when compared with healthy controls [33, 34] . The paediatric patients with anti-BAFF antibodies in the highest quartile had significantly higher SLE Disease Activity Index (SLEDAI) scores, implicating an association between anti-BAFF autoantibodies and disease activity [34] . These findings also imply that autoantibodies against BAFF might not temper, but rather worsen, the course of disease.
The aim of our study was to determine the association between levels of serum BAFF, anti-BAFF antibodies and BAFF-immunoglobulin G (IgG) complexes and SLE disease activity using a large cohort of well-defined patients with SLE.
M A T E R I A L S A N D M E T H O D S

Patients and controls
Serum samples of 178 patients were provided by the Swiss SLE Cohort Study (SSCS), which prospectively enrols adult SLE patients fulfilling the American College of Rheumatology classification criteria [35, 36] . The collection of clinical data and corresponding serum samples used in this study was performed between 2008 and 2013 at four Swiss university hospitals. All patients with a complete disease activity score (SLEDAI), physician's global assessment (PGA) and corresponding biomaterial were included in our study. SSCS is approved by the ethical committees of all contributing centres. All participating individuals provided written informed consent to the study protocol. Visits were scheduled yearly or more often if necessary to include time points with disease flares. The number of visits per patient analysed in our study ranged from one to five. Overall, 373 samples from 178 patients were studied. Disease activity was estimated by SLEDAI and PGA. Patients with inactive/minimally active disease were defined as having a SLEDAI score < 6 [5, 37] . The characteristics of our patient cohort are presented in Table 1 . Sixty-four sera samples obtained from normal serum donors (NSDs) served as controls. All sera were frozen and stored at À80 C prior to the measurements.
Enzyme-linked immunosorbent assay (ELISA)
BAFF assay. BAFF concentrations were measured as described by Kreuzaler et al. [38] using two different rat monoclonal antibodies against two different epitopes of human BAFF Affinity measurement of anti-BAFF antibody. The concentration of free anti-BAFF antibodies was estimated using a competition ELISA. Briefly, the mixture of soluble rh BAFF in increasing concentrations (5 Â 10 À6 À5 Â 10 À8 M) and serum from patient SLE 1 diluted 1/1500 was incubated for 2 h onto the plate coated with 1 lg/mL BAFF. An alkaline phosphatase-conjugated goat anti-human IgG Fcc antibody was added. Absorbance at 405 nm represents anti-BAFF antibodies bound to the plate-bound BAFF used to calculate the percent inhibition of maximum binding and K d by Scatchard plot analysis (GraphPad Prism version 6, GraphPad Software, La Jolla, CA, USA).
BAFF-IgG complex assay. BAFF-IgG complexes were assessed by ELISA. For this, sera diluted 1/100 in PBSTF were applied in duplicates to 96-well plates coated with 5 lg/mL rat anti-human BAFF monoclonal antibody 2.81 and blocked with PBSTF. A 1:1 dilution was used for the samples obtained after separation by FPLC. After incubation for 2 h, detection of bound BAFF-IgG complexes was conducted with an alkaline phosphatase-labelled goat anti-human IgG Fcc antibody for 1 h.
Statistical analysis
Due to asymmetric distribution, data are given as medians with interquartile ranges (IQRs). For comparisons of two groups, two-tailed Mann-Whitney and chi-square tests were used. Correlations between variables were assessed by Spearman tests. For multiple comparisons we used two-tailed Kruskal-Wallis tests. For the investigation of differences in patients with modifications in disease activity at follow-up, a two-tailed Wilcoxon matched pairs test was conducted. Because of multiple tests, P-values obtained when analysing the patients from the SSCS were adjusted using Bonferroni correction. All tests were performed using GraphPad Prism version 6. P-values 0.05 were considered statistically significant. A linear mixed model approach with autoregressive covariance structure on the repeated with several follow-up samples measurements was performed to estimate the relationship between BAFF-IgG complexes and the SLEDAI as well as the PGA in patients.
R E S U L T S
Detection and characterization of IgG autoantibodies targeting BAFF in SLE patients
In order to detect autoantibodies with reactivity to BAFF, we first established an indirect ELISA using serum samples of six SLE patients with active disease and six healthy blood donors. A significant difference in signal intensity between these two groups was found (P ¼ 0.009, data not shown). To verify the specificity of our assay for monomeric anti-BAFF Ig, we then separated the sera of the six SLE patients and one healthy donor by FPLC based on protein size. Figure 1A In addition, sera derived from two SLE patients treated for several months with belimumab were analysed before and immediately after the administration of belimumab. As expected, there was an overall increase of total IgG anti-BAFF antibody levels after therapy with belimumab. Interestingly, the signal peak of the anti-BAFF antibody profile was much broader compared with anti-BAFF antibody-positive sera without belimumab treatment ( Figure 1D ), most likely caused by saturation of the assay with large amounts of IgG anti-BAFF as a result of the long period of therapy with belimumab. Further dilution (1:100) of the fractions led to a smaller distribution of the positive signal, supporting our assumption (data not shown).
Detection of artificial BAFF-anti-BAFF antibody complexes and BAFF-IgG complexes in SLE sera
In order to be able to quantify potentially occurring serum complexes of BAFF and anti-BAFF autoantibodies, we established an ELISA to quantify complexes containing both BAFF and IgG antibodies. For this purpose we first prepared constructs consisting of human rhBAFF and monoclonal rat anti-BAFF antibody 4.62 mixed in two different ratios (Figure 2A ). Mixing BAFF and monoclonal antibody in a 1:1.4 ratio predominantly led to large complexes with a small proportion of small complexes. A signal shift towards smaller
complexes occurred after changing the BAFF antibody ratio towards an excess of BAFF (BAFF:mAb 4.62 ratio 4:1). In comparison, the combination of human BAFF and belimumab in a 1:1.4 ratio led to a single signal peak in fractions 24 and 25, suggesting the formation of smaller complexes ( Figure 2B ). Taken together, the data suggest that the size and structure of BAFF-IgG anti-BAFF complexes depend on both the type of anti-BAFF antibody and the ratio of BAFF and anti-BAFF antibodies.
In order to study the presence of complexes containing BAFF and IgG in human sera, we screened samples from six SLE patients with active disease showing significantly higher signal intensities than sera from six healthy donors (P ¼ 0.015, data not shown). The size-dependent localization of BAFF-IgG complexes in the serum fractions from six SLE patients and one healthy donor are shown in Figure 2C . Taken together, SLE patients clearly differ from each other in their signal profiles. However, the signal peak was always found in fractions 25 and 26, suggesting that the majority of complexes are small, with some patients also having large BAFF-IgG complexes. In comparison, the presence of belimumab was associated with large BAFF-IgG complexes in one of two patients ( Figure 2D ) and signal intensities were higher after belimumab administration than in the same patients before belimumab.
Association of levels of BAFF, IgG anti-BAFF and BAFF-IgG complexes with SLE disease manifestations
In order to study the relationship between serum BAFF, IgG anti-BAFF and BAFF-IgG complexes and their association with SLE disease manifestations, we analysed serum samples derived from 178 patients included in the SSCS and 64 NSDs. In line with previous studies, median levels of BAFF in SLE patients were significantly higher than in NSDs (Supplementary data, Figure S1A ). Serum BAFF levels correlated weakly but significantly with levels of BAFF-IgG complexes and IgG anti-BAFF antibodies (Supplementary data, Figure S2 ). With regard to the association of BAFF levels with SLE manifestations, we observed a positive correlation between BAFF levels and erythrocyte sedimentation rate and proteinuria, and leucopenia in patients was associated with significantly higher serum BAFF levels (Table 2) . Moreover, BAFF levels weakly correlated with SLEDAI scores and were significantly increased in patients with high disease activity as assessed by the attending physician (defined as PGA !2).
Analysis of IgG anti-BAFF antibodies did not reveal a significant difference between patients and NSDs (Supplementary data, Figure S1B ). However, as demonstrated in Table 2 , patients with anti-dsDNA, leucopenia and PGA !2 had significantly higher serum levels of IgG anti-BAFF antibodies than those without.
Regarding BAFF-IgG complexes, we found significantly higher levels in SLE patients than in NSDs (Supplementary data, Figure S1C ) and a strong correlation was found between levels of IgG anti-BAFF and BAFF-IgG complexes (Supplementary data, Figure S2 ). Assessment of serum levels of BAFF-IgG complexes in relation to SLE disease manifestations revealed a strong correlation of BAFF-IgG complex levels with the SLEDAI and low complement C3 and C4 (Table 2, Figure  4D -E)). Increased levels of BAFF-IgG complexes were found in patients with anti-dsDNA positivity and those with a history of lupus nephritis. Furthermore, BAFF-IgG complexes levels also strongly correlated with anti-dsDNA titers ( Figure 4F ). In addition, patients with increased disease activity (PGA !2) had significantly higher levels of BAFF-IgG complexes than patients with low disease activity (PGA 1). In contrast, we could not identify significant differences in dependency of the current treatment regimen besides those described for belimumab (data not shown).
Extension of our analysis to all patient visits available (n ¼ 373) confirmed the associations of BAFF, IgG anti-BAFF antibodies and BAFF-IgG complexes with SLE disease manifestations (Supplementary data, Table SI ). Furthermore, a linear mixed model analysis revealed a positive correlation between BAFF-IgG complex levels and the SLEDAI for consecutive study visits (R ¼ 0.2944, 95% CI 0.1401-0.4384), and BAFFIgG levels correlated even stronger with the PGA (R ¼ 0.6274, 95% CI 0.4332-0.7919).
In subgroup analyses, we selected a subgroup of SLE patients with active disease as defined by PGA !1. In this subgroup, both BAFF and BAFF-IgG complexes significantly correlated with the SLEDAI score ( Figure 3 ). In addition, BAFF levels and 
| | | | | | | | | | | | | | |
BAFF-IgG complexes were significantly increased in those patients of the subgroup with highly active disease defined by an additional SLEDAI !6 (Figure 4) . Finally, in order to evaluate changes of BAFF, IgG anti-BAFF and BAFF-IgG complex levels over time and dependence on disease activity, samples of patients that experienced a reduction of disease activity, defined as a decrease of PGA by !2 points or of the SLEDAI by !6 points at follow-up, were analysed. Indeed, serum levels of BAFF-IgG complexes significantly decreased with decreasing disease activity scores ( Figures  5 and 6 ), while levels of BAFF and anti-BAFF antibodies remained stable. FIGURE 4: Serum levels of (A) BAFF, (B) IgG anti-BAFF antibodies and (C-F) BAFF-IgG complexes in 75 patients with active disease based on a PGA !1 comparing patients with high disease activity (SLEDAI !6; n ¼ 50) versus those with low disease activity (SLEDAI <6; n ¼ 25). Analyses were performed considering first visits only. Data are presented as median with interquartile range. *P < 0.05; ** P < 0.01. Correlations between serum levels of BAFF-IgG complexes and complement C3 and C4 in 178 SLE patients (D-E). Correlation between levels of BAFF-IgG complexes and anti-dsDNA antibodies in the first-visits samples from 152 SLE patients from the Swiss SLE Cohort Study (F). NS, not significant; OD, optical density.
D I S C U S S I O N
In the present study we describe for the first time complexes consisting of BAFF and IgG occurring in the sera of SLE patients as being significantly higher than in healthy blood donors. Moreover, in a large cohort of SLE patients, BAFF-IgG complexes were found to strongly correlate with complement consumption, anti-dsDNA levels, overall disease activity and the occurrence of lupus nephritis.
In the current study we also assessed serum levels of BAFF and IgG anti-BAFF antibodies. While IgG anti-BAFF autoantibodies showed no association with clinical manifestations of SLE, an association of serum BAFF levels with SLE disease activity and renal involvement could be confirmed, supporting previous studies that suggested a link between BAFF and SLE disease manifestations [14, 15, 17-19, 22, 38] .
In contrast to serum BAFF levels, we could not demonstrate an overall increase of IgG anti-BAFF autoantibody levels in adult SLE patients, although we saw significantly elevated autoantibodies in patients with highly active disease as well as in some patients with anti-dsDNA positivity. We also could not detect an obvious association between IgG anti-BAFF and SLE disease activity or renal disease. Thus our findings are not in line with previous data [33, 34] . One explanation for this discrepancy might be differences in patient characteristics. The paediatric patients in the previously published study had higher disease activity, were more often positive for anti-dsDNA antibodies and had a higher prevalence of renal involvement than the adult patients investigated in our study. In addition, a large subset of the paediatric patients (71 of 122) had new-onset disease, which was the case in only a minority of our SLE patients. Last, the detection of anti-BAFF antibodies with our assay was limited to the quantification of IgG autoantibodies, while Haddon et al. [34] determined anti-BAFF antibodies independent of the Ig class. Using the same secondary antibody, we detected small amounts of anti-BAFF autoantibodies with IgM size (data not shown), indicating that anti-BAFF antibodies mostly, but not exclusively, consist of IgG. The main finding of our study was the identification of BAFF-IgG complexes circulating in the sera of SLE patients. We demonstrated that BAFF-IgG complexes are strongly associated with anti-dsDNA levels, complement consumption, overall disease activity and a history of lupus nephritis. These observations suggest a functional role of BAFF-IgG complexes in the pathogenesis of SLE. Sarantopoulos et al. [39] proposed a model of how BAFF, anti-BAFF autoantibodies and BAFF-IgG complexes could interact with each other, leading to active disease [31] . They hypothesized that the excess of soluble BAFF in SLE patients might stimulate autoreactive B-cells to produce anti-BAFF autoantibodies, which then might give rise to the formation of BAFF-IgG complexes. Positive correlations between the three parameters as observed in our study could well fit with this concept. However, the hypothesis that anti-BAFF autoantibodies neutralize pro-inflammatory BAFF by interrupting its interaction with the BAFF receptor (BAFF-R) and worsening the course of disease at the same time, as described by Price et al. [33] , appears counterintuitive. Our failure to show an association between anti-BAFF antibody levels and SLE disease activity could be due to the presence of both inhibitory as well as stimulatory anti-BAFF autoantibodies, particularly when taking into account the heterogeneity of autoantibodies in patients with autoimmune diseases. In addition, BAFF-IgG complexes might strongly differ in their functionality. For instance, complexes of human BAFF and belimumab formed in our in vitro experiments most likely temper SLE disease activity by antagonizing BAFF. In contrast, the BAFF-IgG complexes observed in the sera of SLE patients were associated with serological and clinical SLE disease activity, in spite of being similar in size to the BAFF-belimumab constructs. As a consequence, the epitope on BAFF targeted by the anti-BAFF antibody might define not only the size and the structure but also the functionality of the BAFF-IgG complexes. This view might be of major importance when designing new therapeutics aimed at interrupting the interaction between BAFF and its receptors [40, 41] . Furthermore, it is possible that IgG autoantibodies binding BAFF close to the epitope recognized by belimumab might impair its binding and lead to lower effectiveness of the drug, as observed in some patients [29, 42, 43] . However, further studies are needed to evaluate BAFF-IgG serum complexes in nonresponders to belimumab. In addition, the precise mechanisms allowing BAFF-IgG complexes to display their function are not known. Based on the present data, we hypothesize that BAFFIgG complexes may favour SLE disease activity by enhancing the activation of B-cells, including autoreactive B-cells. This effect could be mediated by the antibody-mediated polymerization of BAFF molecules, which would favour their interaction with BAFF-R. In line with this hypothesis, it has been previously demonstrated in mice that recombinant BAFF forms oligomeric complexes before binding to BAFF-R, resulting in enhanced Bcell survival [44] . A similar concept has been described for interleukin-2, where complexes consisting of interleukin-2 and monoclonal antibodies selectively enhance either stimulatory or inhibitory properties of the cytokine [45] . In ongoing studies we are elucidating the functional role of BAFF-IgG complexes in B-cell activation.
Our BAFF-IgG complex assay has some limitations. First, we cannot fully exclude interactions with other immune complexes. In addition, a more detailed analysis of the content of the detected BAFF-IgG complexes is required. Although we think that BAFF-IgG complexes mostly consist of BAFF and anti-BAFF autoantibodies, we cannot exclude the possibility of the presence of soluble BAFF receptors or membrane vesicles as part of the complexes mediating the binding of IgG and BAFF [46] [47] [48] . Last, before proposing BAFF-IgG complexes as a new biomarker of SLE disease activity, further studies will need to compare BAFF-IgG not only with classical immune complex assays but also with currently used routine biomarkers such as anti-dsDNA, complement components and anti-C1q antibodies.
In conclusion, serum BAFF-IgG complexes strongly correlate with clinical and serological SLE disease activity, suggesting their involvement in the pathogenesis of SLE. Our results encourage the future use of BAFF-IgG complexes as a biomarker of SLE.
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